Frazier Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Frazier Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,026	Closed	-$255K	–	43
2021 Q4	$255K	Hold	17,026	–	–	0.02%	43
2021 Q3	$507K	Hold	17,026	–	–	0.04%	41
2021 Q2	$575K	Hold	17,026	–	–	0.05%	34
2021 Q1	$707K	Hold	17,026	–	–	0.06%	35
2020 Q4	$1.03M	Hold	17,026	–	–	0.08%	34
2020 Q3	$2.27M	Hold	17,026	–	–	0.2%	25
2020 Q2	$2.87M	Hold	17,026	–	–	0.25%	21
2020 Q1	$2.45M	Hold	17,026	–	–	0.28%	22
2019 Q4	$5.62M	Hold	17,026	–	–	0.94%	15
2019 Q3	$8.51M	Hold	17,026	–	–	2.66%	13
2019 Q2	$10.3M	Hold	17,026	–	–	2.65%	12
2019 Q1	$10.4M	Buy	17,026 +977	+6%	+$533K	2.5%	12
2018 Q4	$5.86M	Sell	16,049 -977	-6%	-$525K	1.51%	14
2018 Q3	$11.5M	Buy	+17,026	New	+$12.1M	2.1%	11

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Frazier Management's NBRV Position: Q1 2022 in Review

Frazier Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2022, closing a stake of 17,026 shares — an estimated $255K sold.

Frazier Management first reported a position in NBRV in Q3 2018 and held it in 14 quarters. The position peaked at $11.5M in Q3 2018. 29 funds tracked by Wall St. Rank hold NBRV as of Q1 2022.

Frazier Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 17,026 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2022, an estimated $255K.
Frazier Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2018 and held it in 14 quarters.
Frazier Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $11.5M in Q3 2018.
29 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.